ASCO Annual Meeting | Conference

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

June 3rd 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

Carfilzomib Tops Bortezomib in Relapsed Myeloma

June 3rd 2015

Progression-free survival in relapsed myeloma doubled among patients treated with carfilzomib, rather than bortezomib, in combination with dexamethasone, a randomized trial showed.

Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS

June 3rd 2015

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

Dr. Cristofanilli on the PALOMA3 Trial for Breast Cancer

June 3rd 2015

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, discusses the PALOMA3 trial.

PD-1/PD-L1 Inhibitors Safe, Effective in Advanced Ovarian Cancer

June 3rd 2015

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

Trabectedin Extends PFS in Phase III Soft Tissue Sarcoma Study

June 3rd 2015

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer

June 2nd 2015

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

Dr. Wolchock on the Phase III CheckMate-067 Melanoma Findings

June 2nd 2015

Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Dr. Spira on Atezolizumab in the POPLAR Study for NSCLC

June 2nd 2015

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).

Dr. Reck Discusses Prognostic and Predictive Factors for OS With Necitumumab in NSCLC

June 1st 2015

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the phase III SQUIRE study.

Largest-Ever Precision Medicine Oncology Trial Ready for Launch

June 1st 2015

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.

ASCO Provides Early Look at CancerLinQ Big Data Initiative

June 1st 2015

At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.

Off-Label Access to Targeted Therapies Offered Through ASCO's First-Ever Clinical Trial

June 1st 2015

Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.

Dr. Creelan Discusses Results of MEDI4736 in Combination With Gefitinib in NSCLC

June 1st 2015

Ben Creelan, MD, medical oncologist with Moffitt Cancer Center, discusses the results from a phase I study of MEDI4736, an anti-PD-L1 antibody in combination with gefitinib, an EGFR inhibitor, in patients with non-small-cell lung cancer (NSCLC).

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

May 31st 2015

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

Eribulin Elicits Survival Advantage in Phase III Sarcoma Study

May 31st 2015

Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.

Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up

May 31st 2015

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

Preventive Neck Lymph Node Surgery Should Become Standard of Care in Early Oral Cancer

May 31st 2015

Elective neck dissection performed at the same time patients have surgery for early-stage, node-negative, oral squamous cell cancer significantly improved overall survival and reduced the risk of death and recurrence when compared with a watchful waiting approach.